WANG Yan, ZOU Huiling, GANG Qiang, SUN Yu. Value of miRNA-93 in early diagnosis of patients with type 2 diabetes mellitus complicated with acute myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2021, 25(18): 111-115. DOI: 10.7619/jcmp.20212960
Citation: WANG Yan, ZOU Huiling, GANG Qiang, SUN Yu. Value of miRNA-93 in early diagnosis of patients with type 2 diabetes mellitus complicated with acute myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2021, 25(18): 111-115. DOI: 10.7619/jcmp.20212960

Value of miRNA-93 in early diagnosis of patients with type 2 diabetes mellitus complicated with acute myocardial infarction

More Information
  • Received Date: July 22, 2021
  • Available Online: September 27, 2021
  • Published Date: September 27, 2021
  •   Objective  To investigate the value of miRNA-93 in early diagnosis of patients with type 2 diabetes mellitus (T2DM) complicated with acute myocardial infarction (AMI).
      Methods  A total of 147 hospitalized T2DM patients with chest pain from October 2018 to January 2021 in Department of Cardiovascular Medicine in Suqian Hospital Affiliated to Xuzhou Medical University were collected, and all the patients were divided into AMI group (n=76) and non-AMI group (n=71) after coronary angiography. The general clinical materials and the cardiac troponin I (cTnI) level within 6 h after onset were collected. Real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) was used to detect the serum expression level of miRNA-93 within 6 h after onset in patients. Receiver operator characteristic (ROC) curve was drawn to evaluate the value of miRNA-93 in the early diagnosis of T2DM complicated with AMI. Multivariate Logistic regression model was used to analyze the risk factors of T2DM patients complicated with AMI.
      Results  There were significant differences in ratio of male cases, history of smoking, history of hypertension, low density lipoprotein cholesterol (LDL-C), cTnI and miRNA-93 between the two groups (P < 0.05). The results showed that the area under the curve (AUC) of miRNA-93 in predicting AMI was 0.884, which was significantly higher than 0.786 of cTnI (P < 0.05). Multivariate Logistic regression analysis showed that miRNA-93 and history of smoking were the independent risk factors for AMI (OR=3.285, 1.864, P < 0.05).
      Conclusion  The miRNA-93 has a good value in early diagnosis of T2DM patients complicated with AMI. As an independent risk factor for AMI in T2DM patients, miRNA-93 may be involved in the pathophysiological process of AMI in T2DM patients.
  • [1]
    LI Y, TENG D, SHI X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369: m997.
    [2]
    AHMAD M I, SHAPIRO M D. Preventing diabetes and atherosclerosis in the cardiometabolic syndrome[J]. Curr Atheroscler Rep, 2021, 23(4): 16. doi: 10.1007/s11883-021-00913-8
    [3]
    GABA P, GERSH B J, ALI Z A, et al. Complete versus incomplete coronary revascularization: definitions, assessment and outcomes[J]. Nat Rev Cardiol, 2021, 18(3): 155-168. doi: 10.1038/s41569-020-00457-5
    [4]
    LIU J, WU J D, LI L B, et al. The role of exosomal non-coding RNAs in coronary artery disease[J]. Front Pharmacol, 2020, 11: 603104. doi: 10.3389/fphar.2020.603104
    [5]
    RABER I, MCCARTHY C P, JANUZZI J L. A test in context: interpretation of high-sensitivity cardiac troponin assays in different clinical settings[J]. J Am Coll Cardiol, 2021, 77(10): 1357-1367. doi: 10.1016/j.jacc.2021.01.011
    [6]
    SOLARO C R, SOLARO R J. Implications of the complex biology and micro-environment of cardiac sarcomeres in the use of high affinity troponin antibodies as serum biomarkers for cardiac disorders[J]. J Mol Cell Cardiol, 2020, 143: 145-158. doi: 10.1016/j.yjmcc.2020.05.010
    [7]
    ZHANG L, DING H, ZHANG Y, et al. Circulating MicroRNAs: biogenesis and clinical significance in acute myocardial infarction[J]. Front Physiol, 2020, 11: 1088. doi: 10.3389/fphys.2020.01088
    [8]
    ALINA I S, MIRUNA-MIHAELA M, NICOLETA-MONICA P F, et al. MicroRNAs in Acute ST Elevation Myocardial Infarction-A New Tool for Diagnosis and Prognosis: Therapeutic Implications[J]. Int J Mol Sci, 2021, 22(9): 4799-4818. doi: 10.3390/ijms22094799
    [9]
    ZOU H L, WANG Y, GANG Q, et al. Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2017, 255(6): 1159-1166. doi: 10.1007/s00417-017-3638-5
    [10]
    中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47(10): 766-783. https://www.cnki.com.cn/Article/CJFDTOTAL-GWXX201504001.htm
    [11]
    中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J]. 中华心血管病杂志, 2017, 45(5): 359-376. doi: 10.3760/cma.j.issn.0253-3758.2017.05.003
    [12]
    DZHOYASHVILI N A, EFIMENKO A Y, KOCHEGURA T N, et al. Disturbed angiogenic activity of adipose-derived stromal cells obtained from patients with coronary artery disease and diabetes mellitus type 2[J]. J Transl Med, 2014, 12: 337. doi: 10.1186/s12967-014-0337-4
    [13]
    LIU J, JIANG M, DENG S, et al. miR-93-5p-containing exosomes treatment attenuates acute myocardial infarction-induced myocardial damage[J]. Mol Ther Nucleic Acids, 2018, 11: 103-115. doi: 10.1016/j.omtn.2018.01.010
    [14]
    NAZARI-SHAFTI T Z, EXARCHOS V, BIEFER H R C, et al. MicroRNA mediated cardioprotection - is there a path to clinical translation[J]. Front Bioeng Biotechnol, 2020, 8: 149. doi: 10.3389/fbioe.2020.00149
    [15]
    MORI M A, LUDWIG R G, GARCIA-MARTIN R, et al. Extracellular miRNAs: from biomarkers to mediators of physiology and disease[J]. Cell Metab, 2019, 30(4): 656-673. doi: 10.1016/j.cmet.2019.07.011
    [16]
    MA Y, PAN C, TANG X, et al. MicroRNA-200a represses myocardial infarction-related cell death and inflammation by targeting the Keap1/Nrf2 and β-catenin pathways[J]. Hellenic J Cardiol, 2021, 62(2): 139-148. doi: 10.1016/j.hjc.2020.10.006
    [17]
    SHI H, SUN H, LI J, et al. Systematic analysis of lncRNA and microRNA dynamic features reveals diagnostic and prognostic biomarkers of myocardial infarction[J]. Aging: Albany NY, 2020, 12(1): 945-964. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM31927529
    [18]
    ZHONG Z, WU H, ZHONG W, et al. Expression profiling and bioinformatics analysis of circulating microRNAs in patients with acute myocardial infarction[J]. J Clin Lab Anal, 2020, 34(3): e23099. doi: 10.1002/jcla.23099
    [19]
    LIU J W, JIANG M, DENG S Q, et al. miR-93-5p-containing exosomes treatment attenuates acute myocardial infarction-induced myocardial damage[J]. Mol Ther Nucleic Acids, 2018, 11: 103-115. doi: 10.1016/j.omtn.2018.01.010
    [20]
    SOHRABIFAR N, GHADERIAN S M H, VAKILI H, et al. MicroRNA-copy number variations in coronary artery disease patients with or without type 2 diabetes mellitus[J]. Arch Physiol Biochem, 2019: 1-7. doi: 10.1080/13813455.2019.1651340
  • Cited by

    Periodical cited type(5)

    1. 黄芳,张纯,陈宝莹,卢肖霞,梁曼谊,罗允内. 穴位贴敷治疗咳嗽变异性哮喘的临床研究. 中国医药科学. 2022(04): 71-73 .
    2. 严瑾,王继鹏. 肺泡气一氧化氮对咳嗽变异性哮喘ICS+LABA治疗反应的意义. 中华肺部疾病杂志(电子版). 2022(05): 673-675 .
    3. 钱星佳,吕红. 从“风”论治咳嗽变异性哮喘的研究概况. 中医临床研究. 2022(21): 48-51 .
    4. 肖超扬. 一氧化氮测定仪诊断小儿咳嗽变异性哮喘的价值体会. 中国医疗器械信息. 2020(20): 68-69 .
    5. 车玲艳,刘建红,樊延平. 苏黄止咳胶囊联合沙美特罗替卡松对咳嗽变异性哮喘患者疗效及对肺功能指标的影响. 山西医药杂志. 2020(23): 3303-3305 .

    Other cited types(4)

Catalog

    Article views (189) PDF downloads (11) Cited by(9)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return